Ig Vena

Human Normal Immunoglobulin (IV), the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases in patients who require immunoglobulin replacement therapy.\n\nGNH India supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Ig Vena is an intravenous immunoglobulin used to replace deficient antibodies in disorders of the immune system.\n\nPrimary immunodeficiency diseases: provides pooled IgG to reduce infection frequency and improve immune protection.\nSecondary immunodeficiency: supplies IgG to support immune function in patients with acquired immune deficiencies.\nPost‑transplant immune support: helps reconstitute antibody levels after bone‑marrow or solid‑organ transplantation.

Ig Vena may cause a range of infusion‑related and systemic reactions.\n\nCommon Side Effects:\n- Headache\n- Fever or chills\n- Nausea or vomiting\n- Fatigue\n- Infusion‑related flushing or erythema\n- Mild hypotension\n\nSerious or Rare Side Effects:\n- Anaphylaxis or severe allergic reaction\n- Thromboembolic events (e.g., deep‑vein thrombosis)\n- Acute renal dysfunction\n- Hemolysis\n- Aseptic meningitis\n- Severe thrombocytopenia

Before initiating Ig Vena therapy, clinicians should evaluate specific risk factors and monitor patients closely.\n\nScreen for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions.\nMonitor renal function: especially in high‑dose or rapid infusions.\nAssess thrombotic risk: avoid in patients with known hypercoagulable states.\nObserve for infusion reactions: start at a slow rate and adjust as tolerated.\nStore at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena can interact with other therapies, requiring careful management.\n\nMajor Interactions (Avoid):\n- Live vaccines: reduced efficacy and potential infection risk.\n- Concurrent high‑dose immunosuppressants: increased susceptibility to infections.\n- C1‑esterase inhibitor therapy: may alter complement activity.\n\nModerate Interactions (Monitor Closely):\n- ACE inhibitors: may enhance hypotensive episodes during infusion.\n- Diuretics: affect fluid balance and renal clearance.\n- Anticoagulants: monitor for bleeding if renal function declines.